Phytoceutica, Inc. of the US to Advance Clinical Trials of TCM for Cancer
4/4/2012 10:11:32 AM
April 3, 2012 -- PhytoCeutica, a Connecticut pharma startup sponsored by Yale University, plans to move its lead drug, PHY906, forward in clinical trials as an adjuvant to chemotherapy. PHY906 is an ancient TCM known as Huang Qin Tang, used for the past 18 centuries as a treatment for diarrhea, nausea and vomiting. Yung-Chi Cheng, PhD, a distinguished pharmacologist at Yale University, discovered the TCM may be a valuable addition to chemotherapy. More details....
comments powered by